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Purpose: To understand the mechanism of the function of paired box 6 (Pax6), a master regulator of eye development
and functions, Pax6-interacting proteins were studied. It is presumed that the interaction of Pax6 with proteins in terms
of morphogenesis and the maintenance of the functional anatomy of the eyes cannot be ignored. The interaction of Pax6
with matricellular protein and transforming growth factors (TGFs) is explored and presented in this report.
Methods: Co-localization was studied through fluorescence microscopy. The physical interaction of Pax6 interacting
proteins was explored through co-immunoprecipitation assay of samples from murine eyes.
Results: It was interesting to observe the co-localization and physical interaction of Pax6, transforming growth factor-
beta (TGF-β), and secreted protein acidic and rich in cysteine (SPARC) in murine eyes.
Conclusions: The interaction of Pax6, TGF-β, and SPARC in murine eyes indicates that Pax6 function is regulated through
TGF-β, and SPARC influences the shuttling of Pax6 via the TGF-β/Smad signaling pathway.
The pivotal role of paired box 6 (Pax6), a transcriptional
regulator, in eyes induction was demonstrated by triggering
eye  formation  at  ectopic  sites  in  Drosophila  [1]  and
vertebrates [2]. Pax6 has been observed to localize in the
nucleus,  as  well  as  in  cytoplasm  [3-6].  It  has  also  been
suggested  that  any  aberration  that  disrupts  Pax6  spatial
confinement  could  create  a  diseased  phenotype  [7,8].
However, the cascade or hierarchy of the “eye specification
gene” [9,10] is not clear.
After looking into the Pax6 interacting protein database
and associated literature, the matricellular proteins and growth
factors that are co-expressed with Pax6 in eyes were examined
because  transforming  growth  factor-β  (TGF-β)  signaling
pathways  have  been  reported  to  contribute  maximally  to
maintaining  the  functional  status  of  eyes  [11].  Previous
findings have indicated that the functional loss of TGF-β
receptor type I in retinal cells results in retinal detachment
[12]. This contributes to cell survival and axon guidance in
the  retina,  as  well  as  in  the  differentiation  of  the  retinal
pigment epithelium [13,14]. The Mad Homology 1 (MH1)
domain  of  mothers  against  decapentaplegic  homolog  3
(Smad3),  a  downstream  target  of  the  TGF-β  signaling
cascade, has been shown to interact with Pax6 [15]. Similarly,
secreted  protein  acidic  and  rich  in  cysteine  (SPARC)-
producing  cells  have  been  identified  in  the  lens,  retinal
pigment epithelium, and corneal epithelial cells [16-19] both
in the nucleus and cytoplasm [20]. The SPARC has been
implicated in cataract and corneal repair [19,21,22], and is
critical for maintaining the lens transparency [23]. It has been
found in vascular endothelial cells of the choroid, and blood
Correspondence  to:  Rajnikant  Mishra,  Department  of  Zoology,
Banaras  Hindu  University,  Varanasi-221005,  India;  Phone:
91-542-6702505;  FAX:  91-542-2368174;  email:
rmishraa@bhu.ac.in
vessels and fibroblasts of the sclera [24]. Crosstalk between
TGF-β and SPARC has also been reported [25]. It is presumed
that SPARC mediates the regulation of Pax6 via the TGF-β/
Smad-dependent signaling pathway. In the present study, the
co-localization  and  interaction  of  Pax6  with  SPARC  and
TGF-β  were  explored  to  generate  insight  into  molecular
network Pax6 function in eyes.
METHODS
Commercial anti-Pax6 (sc-32766; Santa Cruz, Santa Cruz,
CA), anti-SPARC (sc-25574; Santa Cruz), and anti-TGF-β
(ab-66043; Abcam, Cambridge, UK) antibodies were used in
this study. The anti-Pax6 antibody is detected at 46 kDa, the
anti-SPARC antibody is recognized at 37 kDa and 25 kDa,
and the anti-TGF-β antibody is detected at 13 kDa when
immunoblotted.  Goat  anti-rabbit  (HP03;  Merck,  Mumbai,
India)  and  goat  anti-mouse  (HP021;  Merck)  Horse-radish
peroxidase (HRP)-conjugated secondary IgG antibodies were
used  for  Enhanced  Chemiluminescence  (ECL)-based
detection.  For  immunofluorochemistry,  goat  anti-rabbit
tetramethyl  rhodamine  isothiocynate  (TRITC)-conjugated
(RTC2; Merck), goat anti-mouse fluorescein isothiocyanate
(FITC)-conjugated (FTC3; Merck) secondary IgG antibodies
and  4',  6-diamidino-2-phenylindole  (DAPI;  Invitrogen,
Eugene, OR) were used.
Co-localization  of  Pax6,  SPARC,  and  TGF-β  by
immunohistochemistry:  Mice  were  anesthetized  with
chloroform and perfused transcardially with ice-cold PBS
followed by 4% paraformaldehyde. Eyes were removed and
post-fixed with 4% formaldehyde overnight, then embedded
in  paraffin  wax.  Serial  sections  (10  μm  thick)  were
deparaffinized by xylene followed by rehydration through
alcohol series (30%, 50%, 70%, 90%, and absolute alcohol).
After antigen retrieval with 0.1% trypsin for 3–5 min, sections
were  blocked  with  1%  BSA  for  30  min  before  double
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951immunostaining. The first set was immunostained with anti-
Pax6  (raised  in  mouse)  +  anti-TGF-β  (raised  in  rabbit)
antibodies, while the second set was immunostained using
anti-Pax6+ anti-SPARC (raised in rabbit) antibodies (dilution
1:200).The  sections  were  then  incubated  for  4  h  at  room
temperature. After the incubation with primary antibodies, the
sections were washed three times for 5 min with 1× PBS and
probed with goat anti-mouse FITC-conjugated secondary IgG
and  goat  anti-rabbit  TRITC-conjugated  secondary  IgG
(dilution  1:700).  Experiments  for  negative  control  were
performed by incubating sections without primary antibodies
and counter stained with DAPI (Invitrogen,), to visualize the
entire  population  of  cells.  All  negative  controls  showed
minimal or no immunofluorescence. Images were scanned
using  a  conventional  fluorescence  microscope  (Leica,
Wetzlar,  Germany).  Merged  images  were  obtained  using
Adobe Photoshop CS4 (Adobe Systems Incorporated, San
Jose, CA) and Image J software.
Immunoprecipitation  and  immunoblotting:
Immunoprecipitation using mouse eye extract with anti-Pax6
and anti-TGF-β antibody was performed using the Protein-G
Immunoprecipitation Kit (116622; Merck). Lysate of eyes
was  prepared  using  immunoprecipitation  (IP)  buffer
containing  0.1%  sodium  dodecyl  sulfate,  0.5%  sodium
deoxycholate,  and  protease  inhibitor  cocktail.  Fifty
microliters of protein-G resin slurry were suspended in three
separate columns, washed twice with IP buffer, and incubated
with the three different antibodies (anti-Pax6, anti-TGF-β, and
anti-SPARC) at 4 °C for 60 min. The columns were again
washed twice with IP buffer and 100 μl of lysate was added
to the columns and incubated for another 60 min at 4 °C. The
columns were washed twice with IP buffer and the protein-G
resin slurry complex was re-suspended in 100 μl of sample
loading buffer. The samples thus prepared were transferred in
separate microcentrifuge tubes, heat denatured for 5 min and
centrifuged briefly at 550× g for 20 s. The supernatant was
resolved  through  sodium  dodecyl  sulfate  PAGE  on  10%
polyacrylamide gel. The resolved proteins were then electro
blotted onto polyvinylidene fluoride (PVDF) membrane. The
membrane containing the pulled-down sample from anti-Pax6
was  probed  using  the  anti-TGF-β  antibody,  and  another
membrane containing the same sample was probed by the anti-
Figure 1. Co-localization and interaction between Pax6 and TGF-β. Fluorescence microscopy images of the retinal region of murine eyes
sections showing co-localization and interaction of Pax6 and TGF-β. ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell
layer. The sections were immunostained with anti-Pax6+anti–transforming growth factor–β (TGF-β). A: The green signal, was detected by
fluorescein isothiocynate (FITC)-conjugated secondary IgG that shows the expression of Pax6, B: the red signals detected by tetra-methyl
rhodamine isothiocynate (TRITC)-conjugated secondary IgG show the expression of TGF-β. C: Merged images show the co-localization of
Pax6+TGF-β. Arrows in the insets (D, E, F) show the magnified images of the expression and co-localization. Negative control for
immunostaining. G: without anti-Pax6 primary antibody but with FITC-conjugated secondary antibody no signals were observed, H: without
anti-TGF-β primary antibody but with TRITC-conjugated secondary antibody no signals were observed, I: blue signal by staining with DAPI
shows the entire population of the cells. J: Co-immunoprecipitation assay between Pax6 and TGF-β that is immunoprecipitated (IP) with anti-
Pax6 and immunoblotted (IB) with anti-TGF- β. The next lane of the blot shows negative control of IP experiment with protein-G slurry
without anti-Pax6 antibody, K: Immunoblotting (IB) with anti-Pax6 for immunoprecipitated (IP) with anti-TGF-β that confirms their physical
interaction. The next lane of the blot shows negative control of IP experiment with protein-G slurry without anti-TGF-β antibody.
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952SPARC antibody. Similarly, the samples immunoprecipitated
with the anti-TGF-β antibody were immunoblotted using the
anti-SPARC  and  anti-Pax6  antibodies,  while  the  sample
immunoprecipitated  with  the  anti-SPARC  antibody  was
probed with the anti-Pax6 and anti-TGF-β antibodies. Protein-
G slurry without primary antibodies was taken as a negative
control  for  all  IP/pull-down  experiments.  No
immunoreactivity was observed after western blot analysis.
Also, liver was taken as one of control as non-Pax6 expressing
tissue. The antigen-antibody complexes were detected using
the ECL system.
RESULTS
Co-localization  and  interaction  of  Pax6  and  TGF-β:  The
expression of Pax6 and TGF-β was observed in the retinal
layers (Figure 1A,B) of murine eyes. It was also observed that
Pax6-expressing cells were positive for TGF-β expression, as
highlighted in the inset (Figure 1D,E). The merged (Figure
Figure 2. Co-localization and interaction between Pax6 and SPARC. Fluorescence microscopy images of the retinal region of murine eyes
sections showing co-localization and interaction of Pax6 and SPARC. ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell
layer. The sections were immunostained with anti-Pax6+anti–SPARC. A: The green signal was detected by fluorescein isothiocynate (FITC)-
conjugated secondary IgG that shows the expression of Pax6. B: the red signals detected by tetra-methyl rhodamine isothiocynate (TRITC)-
conjugated secondary IgG show the expression of SPARC. C: Merged images show the co-localization of Pax6+SPARC. Arrows in the insets
(D, E, F) show the magnified images of the expression and co-localization. Negative control for immunostaining. G: without anti-Pax6 primary
antibody but with FITC-conjugated secondary antibody no signals were observed, H: without anti-SPARC primary antibody but with TRITC-
conjugated secondary antibody no signals were observed, I: blue signal by staining with DAPI shows the entire population of the cells. J: Co-
immunoprecipitation assay between Pax6 and SPARC that is immunoprecipitated (IP) with anti-Pax6 and immunoblotted (IB) with anti-
SPARC. The next lane of the blot shows negative control of IP experiment with protein-G slurry without antibodies. K: Immunoblotting (IB)
with anti-Pax6 for immunoprecipitated (IP) with anti-SPARC that confirms their physical interaction. The next lane of the blot shows negative
control of IP experiment with protein-G slurry with anti-Pax6 antibody, immunoblotting with anti-Pax6 using liver as non-Pax6 expressing
tissue, and eye lysate as a positive control showing specificity of anti-Pax6.
Figure  3.  Interaction  between  TGF-β
and  SPARC.  A:  Co-
immunoprecipitation  assay  between
TGF-β  and  SPARC  that  is
immunoprecipitated  (IP)  with  anti-
TGF-β  and  immunoblotted  (IB)  with
anti-SPARC.  B:  Immunoblotting  (IB)
with  anti-TGF-β  for
immunoprecipitated  (IP)  with  anti-
SPARC  that  confirms  their  physical
interaction.
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9531C,F) image indicates co-localization of Pax6 and TGF-β.
Section without primary antibodies (i.e., anti-Pax6 antibody,
(Figure  1G;  anti-TGF-β  antibody,  Figure  1H),  have  been
taken  as  negative  control  to  show  the  specificity  of  the
antibodies. Section was counterstained with DAPI (Figure 1I)
to  visualize  the  entire  population  of  the  cells.  Moreover,
physical interactions between Pax6 and TGF-β (Figure 1J), as
well as TGF-β and Pax6 (Figure 1K), were confirmed by co-
immunoprecipitation  (Co-IP)  assay.  Negative  controls  for
anti-Pax6 and anti-TGF-β antibodies by incubating protein-G
slurry without primary antibody showed no immunoreactivity
when immunoblotted with anti-TGF-β(Figure 1J) and anti-
Pax6 (Figure 1K) antibodies, respectively.
Co localization and interaction between Pax6 and SPARC, as
well  as  SPARC  and  TGF-β:  The  expression  of  Pax6  and
SPARC was observed in the retinal layers (Figure 2A,B,D,E).
Double  immunostaining  using  anti-Pax6  and  anti-SPARC
antibody showed immunoreactive cells. The merged (Figure
2C,F)  image  indicates  the  co-localization  of  Pax6  and
SPARC. Negative controls without anti-Pax6 (Figure 2G) and
anti-SPARC  antibodies  (Figure  2H)  do  not  show
immunofluorescence. The physical interaction between Pax6
and SPARC was also confirmed by Co-IP assay (Figure 2J).
It was also interesting to observe the interaction between
SPARC  and  Pax6  when  cross  checked  (Figure  2K).
Experiments  for  negative  controls  without  anti-SPARC
antibody showed no immunoreactivity when immunoblotted
with  anti-SPARC  (Figure  2J).  No  immunoreactivity  was
observed in liver, a non-Pax6 expressing tissue, but eyes lysate
does (Figure 2K). The physical interaction between SPARC
and TGF-β (Figure 3A,B) was also confirmed by Co-IP assay.
DISCUSSION
The co-localization and interaction of Pax6 with SPARC and
TGF-β provide direct evidence of their involvement in the
cascade of Pax6 function. One previous report has indicated
the cell-type-specific response of TGF-β but relatively weak
DNA-binding  affinity  of  Smad  [26].  Therefore,  the
transcriptional efficiency of TGF-β is likely to be influenced
by interactions with other transcription factors or other target
proteins in a tissue-specific manner. Since the contribution of
TGF-β to the development and function of murine eye is well
Figure 4. Presumptive model shows the interaction of Pax6 with SPARC that influences shuttling of Pax6 from nucleus to cytoplasm and the
interaction of the Pax6/SPARC complex with TGF-β to complete the Pax6 nucleocytoplasmic shuttling cycle.
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954established [11], the interaction of Pax6 with TGF-β suggests
that the activity of Pax6 can be regulated via TGF-β signaling
pathways.  It  also  suggests  that  the  biological  processes
regulated by TGF-β signaling pathways may involve Pax6 in
a tissue-specific manner.
The co-localization and interaction of Pax6 with SPARC
(Figure 2) indicates the involvement of a critical phenomenon
of shuttling Pax6 between the nucleus and cytoplasm (Figure
4). It is likely that Pax6-associated phenotypes of the lens,
retina, cornea, and iris are mediated through SPARC [16-22].
Moreover, in agreement with previous work, which found that
there  is  a  functional  intersection  between  the  pathways
activated by TGF-β and SPARC [25], we conducted another
set  of  experiments  to  investigate  the  interaction  between
SPARC  and  TGF-β  (Figure  3A,B).The  crosstalk  between
TGF-β  and  SPARC  also  supports  the  claim  that  there  is
SPARC-mediated regulation of Pax6 in the TGF-β signaling
pathway.  The  interaction  between  TGF-β  and  SPARC
indicates that the biological processes involving SPARC may
also be regulated by TGF-β signaling pathways in murine
eyes.
These  findings  are  presumed  to  provide  a  novel
regulatory mechanism of Pax6 in the murine eye through
interaction-mediated translocation or compartmentalization.
Smad3,  a  downstream  target  of  TGF-β,  also  translocate
rapidly  in  the  nucleus  in  response  to  TGF-β-mediated
activation [27-29]. Pax6, associated with Smad3 [15], may be
translocated  to  the  nucleus  along  with  Smad3.  Inside  the
nucleus, SPARC interacts with the Pax6/Smad3 complex and
facilitates the regulation of Pax6-induced genes, since the
binding affinity of Smad is relatively weak [26]. The nuclear
retention of the Pax6/Smad3 complex may also be due to
interaction with SPARC. Reports have also suggested that the
Smad complex dissociates in the nucleus and is exported to
the  cytosol  [30,31].  In  the  cytoplasm,  the  Pax6/SPARC
complex may stimulate TGF-β signaling, completing the Pax6
nucleocytoplasmic shuttling cycle (Figure 4).
As a result of the considerations discussed above, our data
suggest that the co-localization and interaction of Pax6 with
TGF-β  (Figure  1)  and  SPARC  (Figure  2)  induce  the
interaction-mediated  regulation  of  Pax6  via  TGF-β/Smad-
dependent signaling pathways (Figure 4). It is presumed that
being a transcriptional regulator, a major fraction of Pax6
remains  localized  in  the  nucleus,  and  a  fraction  of  Pax6
interacts with compartment-specific nuclear or cytoplasmic
proteins in Pax6-expressing tissues. The nuclear distribution
of Pax6 might be due to the high-affinity interaction between
Pax6 and other transcription factors in the nucleus, as well as
the matricellular protein SPARC.
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